Pharmaceutical

Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2017. As quoted in the press release: For the year ending December 31, 2018, the Company expects total revenue in the range of $70-$78 million, EBITDA of $3-$6 million, gross margin in …

Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

For the year ending December 31, 2018, the Company expects total revenue in the range of $70-$78 million, EBITDA of $3-$6 million, gross margin in the range of 35-40%, and is planning to invest $13-$15 million in the R&D pipeline.

“In the fourth quarter, the Company rebounded from a challenging third quarter and posted increased revenues for both our US portfolio of topical and injectable pharmaceutical products and our growing business in Canada” said Jason Grenfell-Gardner, President and Chief Executive Officer.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20197.61+15.69
TSXV702.09-3.49
DOW31887.13+625.23
S&P 5003969.22+67.86
NASD11498.81+144.20
ASX7145.60+81.10

COMMODITIES

Commodities
Gold1852.86+7.08
Silver21.790.00
Copper4.33+0.06
Palladium1987.50+20.50
Platinum960.50+1.50
Oil109.88-0.40
Heating Oil3.63+0.01
Natural Gas8.63+0.54

DOWNLOAD FREE REPORTS

×